- Home
- Products
- Customized ADCs
- CD33
- Anti-CD33 (Lintuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-CD33 (Lintuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-817)
This ADC product is comprised of an anti-CD33 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD33
- Alternative Names
- CD33; CD33 molecule; CD33 antigen (gp67); myeloid cell surface antigen CD33; FLJ00391; p67; sialic acid binding Ig like lectin 3; SIGLEC 3; SIGLEC3; gp67; sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3; SIGLEC-3;
- Target Entrez Gene ID
- 945
- Target UniProt ID
- P20138
- Overview
- CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins.
- Overview
- Humanized Anti-CD33 IgG1-kappa antibody, Lintuzumab
- Generic name
- Lintuzumab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD5 (Telimomab aritox)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-935)
- Anti-EGFR (Futuximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1050)
- Anti-GD2 (Dinutuximab)-SMCC-DM1 ADC (CAT#: ADC-W-2006)
- Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2526)
- Anti-MUC16 (Abagovomab)-MC-MMAF ADC (CAT#: ADC-W-1636)
- Anti-NGF (Tanezumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1675)
- Anti-IL22 (Fezakinumab)-SPDB-DM4 ADC (CAT#: ADC-W-1341)
- Anti-CD79b (SN8)-Mc-MMAF ADC (CAT#: ADC-W-225)
- Anti-CD5 (Zolimomab aritox)-MC-MMAF ADC (CAT#: ADC-W-928)
- Anti-ERBB2-SPP-DM1 ADC (CAT#: ADC-W-605)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-817. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-464 | Anti-CD33 (clone hP67.6)-AcBut-Calicheamicin ADC | AcBut (4-(4-acetylphenoxy)butanoic acid) | Calicheamicin |
ADC-W-480 | Anti-CD33 (huMy9-6)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-115 | Anti-CD33 (clone h2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2539 | Anti-CD33 (Gemtuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-114 | Anti-CD33 (clone m2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-2553 | Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2576 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2582 | Anti-CEACAM5-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2603 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
CAT# | Product Name | Linker | Payload |
ADC-W-2594 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2603 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2559 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2609 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.